Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V

   published on

   15.03.2024

   Document type

   PDF document, 272 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A23-129_en

   Download file : Extract of dossier assessment (PDF document, 272 kB, DE, not accessible)
2. Dossier assessment

   Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V

   published on

   15.03.2024

   Document type

   PDF document, 414 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A23-129

   Download file : Dossier assessment (PDF document, 414 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A23-129

Commission

Commission awarded on 11.12.2023 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Skin and hair

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-129_en